U.S. markets closed

Advaxis, Inc. (ADXS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.4180-0.0212 (-4.83%)
At close: 4:00PM EDT

0.4200 0.00 (0.48%)
After hours: 4:28PM EDT

Sign in to post a message.
  • A
    Advaxis, Inc. (NASDAQ: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that the Company has received the second milestone payment related to its licensing agreement for ADXS31-164, also known as ADXS-HER2, to OS Therapies for evaluation in the treatment of osteosarcoma in humans.
  • j
    I'm practicing a law not to lose money since I lost a lot 10 years ago. I bought it for 0.89, but I'm going to sell it higher than this price.
  • E
    time to load up $2-5 soon great news gaining momentum
  • R
    I believe this will go to $10! Everyone, just hold!
  • G
    From .30 PUBLIC offering in November to 1.57. From .7921/.70 DIRECT offering to $_____??? Price to book ~ 1.75 , very low compared to industry average of 8.93 Current Ratio ~ 9.48 , among the very best in the industry Cash until 2Q 2022 before offering, after offering could be good until 2023 Pipelines/ partnerships/ milestone payment, all good news so far While many retail traders got scared, tutes are loading. OVERSOLD, UNDERVALUED, HEAVILY SHORTED. Nearly all bios red, you know what they say, BUY when there's BLOOD on the streets. Do your DD. 1
  • a
    Buy Buy Buy ADXS going to hit triple. Robinhood joined ADXS!!!!! GLAL
  • r
    If you ever see someone posting over and over again that a stock is bad, chances are they're trying to short it to make the price go down.
  • M
    It's Tyler Durdin that is keeping the price down. He is afraid he will have to buy his own stocks.
  • A
    Guys buy more shares and hold anytime TYLER DURDIN posts!
  • L
    NEWS from today , 4/12, following presentation from this past Saturday (4/10/2021)

    Positive BioMarker Data

    Advaxis Saturday Morning Highlighted Presentation Of Translational Biomarker Data From Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial At American Association For Cancer Research Meeting
    4/12/21, 10:18 AM
    April 12, 2021 10:18 AM ET (BZ Newswire) -- News
    Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, and Precision for Medicine, a specialized services company supporting next generation approaches to drug development and commercialization, today announced data on the development of a novel flow immunophenotyping assay to accurately evaluate total PD-1 expression as a pharmacodynamic marker during PD-1 blockade, and translational data demonstrating immune responses correlated to observed clinical benefit from the Company’s ongoing Phase 1/2 study evaluating ADXS-503 in combination with KEYTRUDA®, presented as a poster at the American Association for Cancer Research (AACR) Annual Meeting 2021. ADXS-503 is the first drug construct from the ADXS-HOT off-the-shelf, cancer-type specific, immunotherapy program which leverages Advaxis’ proprietary Lm technology platform to target hotspot mutations that commonly occur in specific cancer types as well as other proprietary, tumor-associated antigens.
    “These presented data suggest this novel immunophenotyping assay has the potential to more accurately measure pharmacodynamic biomarkers in immunotherapy,” said Ken Berlin, Chief Executive Officer of Advaxis. “This assay enables the detection of both free and drug-bound PD-1 expression, independent of PD-1 receptor status or interference due to PD-1 blockade, enabling the accurate evaluation of PD-1 expression in patients undergoing treatment with pembrolizumab. We believe this is another important step forward in further understanding immune responses in patients treated with immunotherapy agents, and may provide important translational insights specific to PD-1 expression and immune modulation which may help shape treatment strategies moving forward.”
    Mr. Berlin continued, “The flow cytometry data confirmed the on-mechanism activation of the innate and adaptive immune systems in patients with observed clinical benefit following treatment with ADXS-503 in combination with pembrolizumab. The demonstrated proliferation and activation of NK cells and CD8 + T cells, plus increased PD-1 expression in diverse immune cells in patients achieving clinical benefit, add to the growing body of evidence which demonstrate the potential of ADXS-503 to re-sensitize or enhance responses to pembrolizumab, even in patients with prior progression. We will continue these analyses with Precision for Medicine on additional patients from our ongoing Phase 1/2 study in NSCLC, and look forward to continued progress as we build upon our previously reported efficacy results which show promising and durable clinical benefit after treatment with ADXS-503, our first off-the-shelf neoantigen immunotherapy candidate.”
    Key presentation highlights:
    Poster presentation titled, “Evaluation of total PD-1 expression using multi-color flow cytometry in metastatic non-small cell lung cancer patients treated with multi-neoantigen vector (ADXS-503) alone and in combination of pembrolizumab to assess T-cell & T-cell memory subsets” presented by Dr.Venkat Mohanram, Senior Scientist at Precision for Medicine.


    • A novel multi-color flow cytometry analysis was developed to accurately identify PD-1 expression on peripheral blood mononuclear cells (PBMCs) of NSCLC patients receiving PD-1/PD-L1 blockade therapy with pembrolizumab and ADXS-503




    • No interference in PD-1 detection due to pembrolizumab blockage was observed, enabling the determination of PD-1 expression independent of PD-1 receptor status, with both free and drug-bound PD-1 detected


  • T
    Just bought 17k shares
  • L
    You can tell shorts are covering or buyers are knocking down to add shares..

    I watch tape all day on SWN/ ADXS.
    Pro trader for 20 years.

    On most downticks .. ADXS is trading small lots

    Price downticks .
    Followed by a block of 40,000 shares or 10,000 shares.

    It CANNOT BE A SHORTSALE, unless the trade occurs on an uptick from previous trade.

    ADXS HAS BOTTOMED. How long it will stay at support .. anyone’s guess.

    But if big buyers return ...
    today ...Tomorow ... in near term , one would summize there is NOT a ton of OVERHELD SUPPLY.

    Most not committed to ADXS. Would have sold in this death run of late .

    I just bought yesterday
    So new ownership is in on ADXS
  • R
    Tomorrow 0.10
  • W
    Wolf of wall street
    This thing will be at a Dollar this week follow the volume
  • b
    I do not understand how this past Monday, 5 days ago adxs was 65 cents and today it is 46 cents, I own 4000 shares at 75 cents. There was no bad news and actually good news where investors can exercise there options at 79 cents this news was on Monday does anybody know why this stock dropped from 65 cents to 46 cents any answered why thanks
  • L
    Anyone shorting ADXS, pumping posts about BK.. lol
    Desperate shorts..
    never happen ... Merck would but them out .

    Don’t forget their Co- trials on Keytruda is the Merck partnership they have...

    From the ADXS website :

    Merck & Co., Inc.
    Advaxis entered into a clinical trial collaboration agreement with Merck to evaluate the combination of Advaxis’ ADXS-PSA with Merck’s PD-1 checkpoint inhibitor KEYTRUDA® (pembrolizumab). The ongoing clinical trial evaluates the safety and efficacy of ADXS-PSA as monotherapy and in combination with KEYTRUDA® in a Phase 1/2 study of patients with previously treated metastatic castration-resistant prostate cancer (mCRPC
  • E
    im holding adxs few yrs im a big believer the pipeline great multiple patterns adxs way undervalue ready to skyrocket easy $10
  • a
    wow robinhood bought all adxs shares. $2 +
  • i
    Hidden Gem